Ontology highlight
ABSTRACT:
SUBMITTER: Vin H
PROVIDER: S-EPMC4366425 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature
Molecular cancer therapeutics 20131029 1
Sorafenib is U.S. Food and Drug Adminstration-approved for the treatment of renal cell carcinoma and hepatocellular carcinoma and has been combined with numerous other targeted therapies and chemotherapies in the treatment of many cancers. Unfortunately, as with other RAF inhibitors, patients treated with sorafenib have a 5% to 10% rate of developing cutaneous squamous cell carcinoma (cSCC)/keratoacanthomas. Paradoxical activation of extracellular signal-regulated kinase (ERK) in BRAF wild-type ...[more]